[Uneven sex distribution in the cardiovascular trials--an exaggerated problem].
Melander
Hans
H
hans.melander@mpa.se
Rastad
Jane Ahlqvist
JA
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001262:Atenolol / Q000627:therapeutic use; D017277:Drug Approval; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D017678:Sex Distribution; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D001262:Atenolol